Ethosuximide
10 NDCs across 8 manufacturers|9 Generic,1 Brand
Ethosuximide is used to treat absence epilepsy, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved before 1982, and the first generic was approved Jan 1, 1982. FDA's Orange Book lists 5 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $2 million on Ethosuximide across 16,000 claims for 2,270 beneficiaries.
Ethosuximide is available as 10 NDCs from 8 manufacturers (9 generic, 1 brand), with NADAC prices from $0.24 to $1.31 per EA — the most expensive product costs about 5.4× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
10
9G / 1B
Manufacturers
8
competing in market
Price Spread
$0.24 – $1.31
per EA, 7 of 10 NDCs
7d Activity
avg +0.6% WoW · of 10 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Epic Pharma LLC manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Anti-epileptic Agent class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
8 manufacturers producing ETHOSUXIMIDE(3 pricing outliers)
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
ZARONTIN 250 MG CAPSULE | $1.3086 per EA | — |
ETHOSUXIMIDE 250 MG CAPSULE | $0.2483 per EA | — |
ETHOSUXIMIDE 250 MG CAPSULE | $0.2435 per EA | -1.94% |
ETHOSUXIMIDE 250 MG CAPSULE | $0.2435 per EA | -1.94% |
ETHOSUXIMIDE 250 MG CAPSULE | $0.2435 per EA | -1.94% |
ETHOSUXIMIDE 250 MG CAPSULE | $0.2435 per EA | -1.94% |
ETHOSUXIMIDE 250 MG CAPSULE | $0.2435 per EA | -1.94% |
ETHOSUXIMIDE 250 MG/5 ML SOLN | $0.1004 per ML | +7.00% |
ETHOSUXIMIDE 250 MG/5 ML SOLN | $0.1004 per ML | +7.00% |
ETHOSUXIMIDE 250 MG/5 ML SOLN | $0.0780 per ML | — |
Frequently Asked Questions
What is Ethosuximide used to treat?
Ethosuximide is used to treat absence epilepsy, per the National Library of Medicine's MED-RT classification.
When did Ethosuximide become available as a generic?
FDA approved the first generic Ethosuximide (ANDA) on Jan 1, 1982. The Orange Book currently lists 5 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Ethosuximide?
In 2024, Medicare Part D spent $2 million on Ethosuximide across 16,000 claims for 2,270 beneficiaries.
How many Ethosuximide products are on the market?
The Ethosuximide drug market contains 10 NDCs from 8 manufacturers — 9 generic and 1 brand product.
What is the price range for Ethosuximide?
NADAC reference prices for Ethosuximide range from $0.2435 to $1.3086 per EA — the most expensive product costs about 5.4× the cheapest. 3 additional products are priced per different units (e.g. liquids per ML) and aren't directly comparable.
Is generic Ethosuximide cheaper than brand?
The average generic NADAC for Ethosuximide is $0.2443 per EA, versus $1.3086 for brand-labeled products — brand versions average about 5.4× the generic price.
Which manufacturers make Ethosuximide?
8 manufacturers list Ethosuximide in NADAC. Ranked by number of NDCs, the largest are Epic Pharma LLC (2), Mylan Pharmaceuticals Inc. (2), Pfizer Inc. (1), Chartwell RX LLC (1), Bionpharma Inc. (1).
How has the price of Ethosuximide changed recently?
Over the past 7 days, 2 Ethosuximide NDCs rose and 5 fell, with a market-wide average change of +0.6%.